View ValuationHarbin Pharmaceutical Group 향후 성장Future 기준 점검 2/6Harbin Pharmaceutical Group (는) 각각 연간 21.3% 및 3.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 22.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 8.3% 로 예상됩니다.핵심 정보21.3%이익 성장률22.15%EPS 성장률Pharmaceuticals 이익 성장17.1%매출 성장률3.3%향후 자기자본이익률8.26%애널리스트 커버리지Low마지막 업데이트17 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • Jul 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥3.71, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total returns to shareholders of 16% over the past three years.공고 • Jun 30Harbin Pharmaceutical Group Co., Ltd. to Report First Half, 2026 Results on Aug 26, 2026Harbin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2026 results on Aug 26, 2026공고 • Jun 03Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 23, 2026Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 23, 2026, at 13:30 China Standard Time. Location: The Company's Meeting Room, Harbin, Heilongjiang ChinaBoard Change • May 20Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Ying Lei was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.공고 • Mar 30Harbin Pharmaceutical Group Co., Ltd. to Report Q1, 2026 Results on Apr 23, 2026Harbin Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026공고 • Dec 26Harbin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026Harbin Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026공고 • Sep 30Harbin Pharmaceutical Group Co., Ltd. to Report Q3, 2025 Results on Oct 25, 2025Harbin Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2025 results on Oct 25, 2025공고 • Jun 30Harbin Pharmaceutical Group Co., Ltd. to Report First Half, 2025 Results on Aug 23, 2025Harbin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2025 results on Aug 23, 2025공고 • May 30Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 20, 2025Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 20, 2025, at 14:00 China Standard Time.공고 • Mar 28Harbin Pharmaceutical Group Co., Ltd. to Report Q1, 2025 Results on Apr 26, 2025Harbin Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2025 results on Apr 26, 2025공고 • Dec 27Harbin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2024 Results on Apr 26, 2025Harbin Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2024 results on Apr 26, 2025Reported Earnings • Oct 26Third quarter 2024 earnings released: EPS: CN¥0.061 (vs CN¥0.053 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.061 (up from CN¥0.053 in 3Q 2023). Revenue: CN¥4.11b (up 8.5% from 3Q 2023). Net income: CN¥164.9m (up 53% from 3Q 2023). Profit margin: 4.0% (up from 2.8% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 22%After last week's 22% share price gain to CN¥3.75, the stock trades at a trailing P/E ratio of 17x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total returns to shareholders of 10.0% over the past three years.공고 • Sep 30Harbin Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024Harbin Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2024 results on Oct 26, 2024Reported Earnings • Aug 23Second quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.022 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.07 (up from CN¥0.022 in 2Q 2023). Revenue: CN¥4.00b (up 6.1% from 2Q 2023). Net income: CN¥166.6m (up 176% from 2Q 2023). Profit margin: 4.2% (up from 1.6% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Board Change • Aug 02High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 4 experienced directors. No highly experienced directors. Chairman Xiaoping Hu is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Valuation Update With 7 Day Price Move • Jul 15Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥3.07, the stock trades at a trailing P/E ratio of 17.2x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total loss to shareholders of 2.8% over the past three years.공고 • Jun 28Harbin Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024Harbin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2024 results on Aug 23, 2024공고 • May 18Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 07, 2024Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 07, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Harbin, Heilongjiang ChinaReported Earnings • Apr 12Full year 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.19 in FY 2022)Full year 2023 results: EPS: CN¥0.16 (down from CN¥0.19 in FY 2022). Revenue: CN¥15.5b (up 12% from FY 2022). Net income: CN¥395.3m (down 15% from FY 2022). Profit margin: 2.6% (down from 3.4% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.공고 • Mar 29Harbin Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024Harbin Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024New Risk • Mar 11New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Large one-off items impacting financial results.Valuation Update With 7 Day Price Move • Feb 05Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to CN¥2.50, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 23x in the Pharmaceuticals industry in China. Total returns to shareholders of 2.9% over the past three years.공고 • Dec 29Harbin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 11, 2024Harbin Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2023 results on Apr 11, 2024Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: CN¥0.053 (vs CN¥0.012 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.053 (up from CN¥0.012 in 3Q 2022). Revenue: CN¥3.79b (up 6.0% from 3Q 2022). Net income: CN¥107.8m (up 213% from 3Q 2022). Profit margin: 2.8% (up from 1.0% in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.공고 • Sep 30Harbin Pharmaceutical Group Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023Harbin Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023Reported Earnings • Aug 25Second quarter 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.022 (up from CN¥0.009 in 2Q 2022). Revenue: CN¥3.77b (up 22% from 2Q 2022). Net income: CN¥60.4m (up 180% from 2Q 2022). Profit margin: 1.6% (up from 0.7% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 12Full year 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.15 in FY 2021)Full year 2022 results: EPS: CN¥0.19 (up from CN¥0.15 in FY 2021). Revenue: CN¥13.8b (up 7.9% from FY 2021). Net income: CN¥464.4m (up 25% from FY 2021). Profit margin: 3.4% (up from 2.9% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.Reported Earnings • Jan 14Full year 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.15 in FY 2021)Full year 2022 results: EPS: CN¥0.17 (up from CN¥0.15 in FY 2021). Revenue: CN¥13.9b (up 8.5% from FY 2021). Net income: CN¥430.6m (up 16% from FY 2021). Profit margin: 3.1% (up from 2.9% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. 4 independent directors (8 non-independent directors). Independent Director Fu Wang was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Oct 28Third quarter 2022 earnings released: EPS: CN¥0.012 (vs CN¥0.06 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.012 (down from CN¥0.06 in 3Q 2021). Revenue: CN¥3.57b (up 7.2% from 3Q 2021). Net income: CN¥34.4m (down 76% from 3Q 2021). Profit margin: 1.0% (down from 4.3% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 27Second quarter 2022 earnings released: EPS: CN¥0.009 (vs CN¥0.12 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.009 (down from CN¥0.12 in 2Q 2021). Revenue: CN¥3.08b (down 10.0% from 2Q 2021). Net income: CN¥21.6m (down 92% from 2Q 2021). Profit margin: 0.7% (down from 7.6% in 2Q 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.Reported Earnings • Apr 29First quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.03 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.04 (up from CN¥0.03 in 1Q 2021). Revenue: CN¥3.33b (up 12% from 1Q 2021). Net income: CN¥100.4m (up 21% from 1Q 2021). Profit margin: 3.0% (up from 2.8% in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. 4 independent directors (7 non-independent directors). Independent Director Fu Wang was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Apr 10Full year 2021 earnings released: EPS: CN¥0.15 (vs CN¥0.43 loss in FY 2020)Full year 2021 results: EPS: CN¥0.15 (up from CN¥0.43 loss in FY 2020). Revenue: CN¥12.8b (up 19% from FY 2020). Net income: CN¥371.1m (up CN¥1.45b from FY 2020). Profit margin: 2.9% (up from net loss in FY 2020). Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.Reported Earnings • Oct 26Third quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.014 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥3.33b (up 17% from 3Q 2020). Net income: CN¥144.4m (up CN¥183.8m from 3Q 2020). Profit margin: 4.3% (up from net loss in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 104 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 19Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.06 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥3.43b (up 49% from 2Q 2020). Net income: CN¥259.2m (up CN¥405.9m from 2Q 2020). Profit margin: 7.6% (up from net loss in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 116 percentage points per year, which is a significant difference in performance.Reported Earnings • Apr 29First quarter 2021 earnings released: EPS CN¥0.03 (vs CN¥0.07 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥2.98b (up 19% from 1Q 2020). Net income: CN¥82.9m (up CN¥269.5m from 1Q 2020). Profit margin: 2.8% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 112 percentage points per year, which is a significant difference in performance.Reported Earnings • Apr 03Full year 2020 earnings released: CN¥0.43 loss per share (vs CN¥0.02 profit in FY 2019)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: CN¥10.8b (down 8.8% from FY 2019). Net loss: CN¥1.08b (down CN¥1.13b from profit in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 104 percentage points per year, which is a significant difference in performance.Is New 90 Day High Low • Jan 25New 90-day low: CN¥2.84The company is down 15% from its price of CN¥3.36 on 28 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 6.0% over the same period.Is New 90 Day High Low • Jan 07New 90-day low: CN¥3.09The company is down 11% from its price of CN¥3.47 on 09 October 2020. The Chinese market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 5.0% over the same period.Is New 90 Day High Low • Dec 14New 90-day low: CN¥3.22The company is down 6.0% from its price of CN¥3.43 on 16 September 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also down 6.0% over the same period.Reported Earnings • Oct 30Third quarter earnings releasedOver the last 12 months the company has reported total losses of CN¥321.1m, with earnings decreasing by CN¥428.0m from the prior year. Total revenue was CN¥11.0b over the last 12 months, down 1.5% from the prior year.Is New 90 Day High Low • Oct 29New 90-day low: CN¥3.33The company is down 6.0% from its price of CN¥3.53 on 31 July 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 9.0% over the same period.이익 및 매출 성장 예측XSSC:600664 - 애널리스트 향후 추정치 및 과거 재무 데이터 (CNY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202817,491602N/A986112/31/202716,939520N/A1,009112/31/202616,403452N/A68813/31/202615,965310566718N/A12/31/202515,964362289440N/A9/30/202515,941449173280N/A6/30/202516,158545467578N/A3/31/202516,208665493599N/A12/31/202416,176629692792N/A9/30/202416,219613210323N/A6/30/202415,895556400492N/A3/31/202415,667450411496N/A12/31/202315,457395863950N/A9/30/202315,3125991,2181,284N/A6/30/202315,096526925988N/A3/31/202314,406487576650N/A12/31/202213,809465532622N/A9/30/202213,0534134137N/A6/30/202212,812151-252-157N/A3/31/202213,15638973166N/A12/31/202112,802371-239-162N/A9/30/202112,879-219-903-811N/A6/30/202112,385-402-511-402N/A3/31/202111,258-808-1,015-902N/A12/31/202010,788-1,078-846-728N/A9/30/202011,009-321-289-209N/A6/30/202011,118-235-334-271N/A3/31/202011,66114-162-107N/A12/31/201911,82556N/A-285N/A9/30/201911,174107N/A390N/A6/30/201910,696-59N/A418N/A3/31/201910,63061N/A372N/A12/31/201810,814346N/A693N/A9/30/201810,910386N/A197N/A6/30/201811,484422N/A-36N/A3/31/201811,790501N/A202N/A12/31/201712,018407N/A149N/A9/30/201712,993441N/A598N/A6/30/201713,180757N/A1,110N/A3/31/201713,761737N/A1,833N/A12/31/201614,127788N/A2,778N/A9/30/201613,662789N/A3,179N/A6/30/201613,830584N/A3,553N/A3/31/201614,435515N/A2,929N/A12/31/201515,856580N/A1,660N/A9/30/201516,038324N/A899N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 600664 의 연간 예상 수익 증가율(21.3%)이 saving rate(2.4%)보다 높습니다.수익 vs 시장: 600664 의 연간 수익(21.3%)이 CN 시장(26.4%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: 600664 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: 600664 의 수익(연간 3.3%)이 CN 시장(연간 16.3%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: 600664 의 수익(연간 3.3%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 600664의 자본 수익률은 3년 후 8.3%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/22 20:03종가2026/07/22 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Harbin Pharmaceutical Group Co., Ltd.는 4명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Wayne HeChina Stock Investment Research Co. Ltd. (DeepValue.online)null Research DepartmentGuotai Haitong/Guotai Junan International Holdings LimitedWen DaiHuatai Research1명의 분석가 더 보기
Valuation Update With 7 Day Price Move • Jul 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥3.71, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total returns to shareholders of 16% over the past three years.
공고 • Jun 30Harbin Pharmaceutical Group Co., Ltd. to Report First Half, 2026 Results on Aug 26, 2026Harbin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2026 results on Aug 26, 2026
공고 • Jun 03Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 23, 2026Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 23, 2026, at 13:30 China Standard Time. Location: The Company's Meeting Room, Harbin, Heilongjiang China
Board Change • May 20Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Ying Lei was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
공고 • Mar 30Harbin Pharmaceutical Group Co., Ltd. to Report Q1, 2026 Results on Apr 23, 2026Harbin Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026
공고 • Dec 26Harbin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026Harbin Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026
공고 • Sep 30Harbin Pharmaceutical Group Co., Ltd. to Report Q3, 2025 Results on Oct 25, 2025Harbin Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2025 results on Oct 25, 2025
공고 • Jun 30Harbin Pharmaceutical Group Co., Ltd. to Report First Half, 2025 Results on Aug 23, 2025Harbin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2025 results on Aug 23, 2025
공고 • May 30Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 20, 2025Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 20, 2025, at 14:00 China Standard Time.
공고 • Mar 28Harbin Pharmaceutical Group Co., Ltd. to Report Q1, 2025 Results on Apr 26, 2025Harbin Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2025 results on Apr 26, 2025
공고 • Dec 27Harbin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2024 Results on Apr 26, 2025Harbin Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2024 results on Apr 26, 2025
Reported Earnings • Oct 26Third quarter 2024 earnings released: EPS: CN¥0.061 (vs CN¥0.053 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.061 (up from CN¥0.053 in 3Q 2023). Revenue: CN¥4.11b (up 8.5% from 3Q 2023). Net income: CN¥164.9m (up 53% from 3Q 2023). Profit margin: 4.0% (up from 2.8% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 22%After last week's 22% share price gain to CN¥3.75, the stock trades at a trailing P/E ratio of 17x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total returns to shareholders of 10.0% over the past three years.
공고 • Sep 30Harbin Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024Harbin Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2024 results on Oct 26, 2024
Reported Earnings • Aug 23Second quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.022 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.07 (up from CN¥0.022 in 2Q 2023). Revenue: CN¥4.00b (up 6.1% from 2Q 2023). Net income: CN¥166.6m (up 176% from 2Q 2023). Profit margin: 4.2% (up from 1.6% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Board Change • Aug 02High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 4 experienced directors. No highly experienced directors. Chairman Xiaoping Hu is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Valuation Update With 7 Day Price Move • Jul 15Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥3.07, the stock trades at a trailing P/E ratio of 17.2x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total loss to shareholders of 2.8% over the past three years.
공고 • Jun 28Harbin Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024Harbin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2024 results on Aug 23, 2024
공고 • May 18Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 07, 2024Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 07, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Harbin, Heilongjiang China
Reported Earnings • Apr 12Full year 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.19 in FY 2022)Full year 2023 results: EPS: CN¥0.16 (down from CN¥0.19 in FY 2022). Revenue: CN¥15.5b (up 12% from FY 2022). Net income: CN¥395.3m (down 15% from FY 2022). Profit margin: 2.6% (down from 3.4% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
공고 • Mar 29Harbin Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024Harbin Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024
New Risk • Mar 11New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Large one-off items impacting financial results.
Valuation Update With 7 Day Price Move • Feb 05Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to CN¥2.50, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 23x in the Pharmaceuticals industry in China. Total returns to shareholders of 2.9% over the past three years.
공고 • Dec 29Harbin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 11, 2024Harbin Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2023 results on Apr 11, 2024
Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: CN¥0.053 (vs CN¥0.012 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.053 (up from CN¥0.012 in 3Q 2022). Revenue: CN¥3.79b (up 6.0% from 3Q 2022). Net income: CN¥107.8m (up 213% from 3Q 2022). Profit margin: 2.8% (up from 1.0% in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
공고 • Sep 30Harbin Pharmaceutical Group Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023Harbin Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023
Reported Earnings • Aug 25Second quarter 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.022 (up from CN¥0.009 in 2Q 2022). Revenue: CN¥3.77b (up 22% from 2Q 2022). Net income: CN¥60.4m (up 180% from 2Q 2022). Profit margin: 1.6% (up from 0.7% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 12Full year 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.15 in FY 2021)Full year 2022 results: EPS: CN¥0.19 (up from CN¥0.15 in FY 2021). Revenue: CN¥13.8b (up 7.9% from FY 2021). Net income: CN¥464.4m (up 25% from FY 2021). Profit margin: 3.4% (up from 2.9% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
Reported Earnings • Jan 14Full year 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.15 in FY 2021)Full year 2022 results: EPS: CN¥0.17 (up from CN¥0.15 in FY 2021). Revenue: CN¥13.9b (up 8.5% from FY 2021). Net income: CN¥430.6m (up 16% from FY 2021). Profit margin: 3.1% (up from 2.9% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. 4 independent directors (8 non-independent directors). Independent Director Fu Wang was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Oct 28Third quarter 2022 earnings released: EPS: CN¥0.012 (vs CN¥0.06 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.012 (down from CN¥0.06 in 3Q 2021). Revenue: CN¥3.57b (up 7.2% from 3Q 2021). Net income: CN¥34.4m (down 76% from 3Q 2021). Profit margin: 1.0% (down from 4.3% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 27Second quarter 2022 earnings released: EPS: CN¥0.009 (vs CN¥0.12 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.009 (down from CN¥0.12 in 2Q 2021). Revenue: CN¥3.08b (down 10.0% from 2Q 2021). Net income: CN¥21.6m (down 92% from 2Q 2021). Profit margin: 0.7% (down from 7.6% in 2Q 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.
Reported Earnings • Apr 29First quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.03 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.04 (up from CN¥0.03 in 1Q 2021). Revenue: CN¥3.33b (up 12% from 1Q 2021). Net income: CN¥100.4m (up 21% from 1Q 2021). Profit margin: 3.0% (up from 2.8% in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. 4 independent directors (7 non-independent directors). Independent Director Fu Wang was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Apr 10Full year 2021 earnings released: EPS: CN¥0.15 (vs CN¥0.43 loss in FY 2020)Full year 2021 results: EPS: CN¥0.15 (up from CN¥0.43 loss in FY 2020). Revenue: CN¥12.8b (up 19% from FY 2020). Net income: CN¥371.1m (up CN¥1.45b from FY 2020). Profit margin: 2.9% (up from net loss in FY 2020). Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.
Reported Earnings • Oct 26Third quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.014 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥3.33b (up 17% from 3Q 2020). Net income: CN¥144.4m (up CN¥183.8m from 3Q 2020). Profit margin: 4.3% (up from net loss in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 104 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 19Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.06 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥3.43b (up 49% from 2Q 2020). Net income: CN¥259.2m (up CN¥405.9m from 2Q 2020). Profit margin: 7.6% (up from net loss in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 116 percentage points per year, which is a significant difference in performance.
Reported Earnings • Apr 29First quarter 2021 earnings released: EPS CN¥0.03 (vs CN¥0.07 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥2.98b (up 19% from 1Q 2020). Net income: CN¥82.9m (up CN¥269.5m from 1Q 2020). Profit margin: 2.8% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 112 percentage points per year, which is a significant difference in performance.
Reported Earnings • Apr 03Full year 2020 earnings released: CN¥0.43 loss per share (vs CN¥0.02 profit in FY 2019)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: CN¥10.8b (down 8.8% from FY 2019). Net loss: CN¥1.08b (down CN¥1.13b from profit in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 104 percentage points per year, which is a significant difference in performance.
Is New 90 Day High Low • Jan 25New 90-day low: CN¥2.84The company is down 15% from its price of CN¥3.36 on 28 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Jan 07New 90-day low: CN¥3.09The company is down 11% from its price of CN¥3.47 on 09 October 2020. The Chinese market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 5.0% over the same period.
Is New 90 Day High Low • Dec 14New 90-day low: CN¥3.22The company is down 6.0% from its price of CN¥3.43 on 16 September 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also down 6.0% over the same period.
Reported Earnings • Oct 30Third quarter earnings releasedOver the last 12 months the company has reported total losses of CN¥321.1m, with earnings decreasing by CN¥428.0m from the prior year. Total revenue was CN¥11.0b over the last 12 months, down 1.5% from the prior year.
Is New 90 Day High Low • Oct 29New 90-day low: CN¥3.33The company is down 6.0% from its price of CN¥3.53 on 31 July 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 9.0% over the same period.